This is the case of urinary tract infections (UTIs) that in a meta-analysis showed no association with the use of SGLT2 inhibitors (Risk Ratio, RR: 0.97; 95% CI: 0.81–1.16) (12). Here, SLC5A2 is linked to urinary tract infection.